Serum levels of 25-hydroxyvitamin D and survival in Norwegian patients with cancer of breast, colon, lung, and lymphoma: A population-based study

Steinar Tretli, Gary G. Schwartz, Peter Abusdal Torjesen, Trude Eid Robsahm

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

Purpose: We investigated the association between serum levels of 25-hydroxyvitamin D (25-OHD) and risk of death in Norwegian cancer patients. Methods: The study population was 658 patients with cancers of the breast (n = 251), colon (n = 52), lung (n = 210), and lymphoma (n = 145), obtained from JANUS, a population-based serum bank in Norway. Serum samples were collected within 90 days of cancer diagnosis and were analyzed for 25-OHD. Patients were diagnosed during 1984-2004 and were followed for death throughout 2008. We used Cox regression models to assess the relationship between serum 25-OHD and risk of death. Results: Three hundred and ninety-nine patients died during follow-up, of whom 343 (86%) died from cancer. Adjusted for sex, age at diagnosis, and season of blood sampling, patients with 25-OHD levels below 46 nmol/L at diagnosis experienced shorter survival. Compared to patients in the lowest quartile of serum 25-OHD, the risk of cancer death among patients in the highest quartile was significantly reduced (HR 0.36 95% CI 0.27, 0.51). The estimated change in risk of cancer death was most pronounced between the first and the second quartile. The associations between 25-OHD levels and survival were observed for all four cancers. Conclusions: Higher circulating serum levels of 25-OHD were positively associated with the survival for cancers of the breast, colon, lung, and lymphoma.

Original languageEnglish (US)
Pages (from-to)363-370
Number of pages8
JournalCancer Causes and Control
Volume23
Issue number2
DOIs
StatePublished - Feb 1 2012

Fingerprint

Colonic Neoplasms
Lymphoma
Breast Neoplasms
Lung
Survival
Serum
Population
Neoplasms
Norway
25-hydroxyvitamin D
Proportional Hazards Models
Colon

Keywords

  • Cancer patients
  • Serum
  • Survival
  • Vitamin D

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Serum levels of 25-hydroxyvitamin D and survival in Norwegian patients with cancer of breast, colon, lung, and lymphoma : A population-based study. / Tretli, Steinar; Schwartz, Gary G.; Torjesen, Peter Abusdal; Robsahm, Trude Eid.

In: Cancer Causes and Control, Vol. 23, No. 2, 01.02.2012, p. 363-370.

Research output: Contribution to journalArticle

@article{afc9cc06968841678e588a65568cd6e5,
title = "Serum levels of 25-hydroxyvitamin D and survival in Norwegian patients with cancer of breast, colon, lung, and lymphoma: A population-based study",
abstract = "Purpose: We investigated the association between serum levels of 25-hydroxyvitamin D (25-OHD) and risk of death in Norwegian cancer patients. Methods: The study population was 658 patients with cancers of the breast (n = 251), colon (n = 52), lung (n = 210), and lymphoma (n = 145), obtained from JANUS, a population-based serum bank in Norway. Serum samples were collected within 90 days of cancer diagnosis and were analyzed for 25-OHD. Patients were diagnosed during 1984-2004 and were followed for death throughout 2008. We used Cox regression models to assess the relationship between serum 25-OHD and risk of death. Results: Three hundred and ninety-nine patients died during follow-up, of whom 343 (86{\%}) died from cancer. Adjusted for sex, age at diagnosis, and season of blood sampling, patients with 25-OHD levels below 46 nmol/L at diagnosis experienced shorter survival. Compared to patients in the lowest quartile of serum 25-OHD, the risk of cancer death among patients in the highest quartile was significantly reduced (HR 0.36 95{\%} CI 0.27, 0.51). The estimated change in risk of cancer death was most pronounced between the first and the second quartile. The associations between 25-OHD levels and survival were observed for all four cancers. Conclusions: Higher circulating serum levels of 25-OHD were positively associated with the survival for cancers of the breast, colon, lung, and lymphoma.",
keywords = "Cancer patients, Serum, Survival, Vitamin D",
author = "Steinar Tretli and Schwartz, {Gary G.} and Torjesen, {Peter Abusdal} and Robsahm, {Trude Eid}",
year = "2012",
month = "2",
day = "1",
doi = "10.1007/s10552-011-9885-6",
language = "English (US)",
volume = "23",
pages = "363--370",
journal = "Cancer Causes and Control",
issn = "0957-5243",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - Serum levels of 25-hydroxyvitamin D and survival in Norwegian patients with cancer of breast, colon, lung, and lymphoma

T2 - A population-based study

AU - Tretli, Steinar

AU - Schwartz, Gary G.

AU - Torjesen, Peter Abusdal

AU - Robsahm, Trude Eid

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Purpose: We investigated the association between serum levels of 25-hydroxyvitamin D (25-OHD) and risk of death in Norwegian cancer patients. Methods: The study population was 658 patients with cancers of the breast (n = 251), colon (n = 52), lung (n = 210), and lymphoma (n = 145), obtained from JANUS, a population-based serum bank in Norway. Serum samples were collected within 90 days of cancer diagnosis and were analyzed for 25-OHD. Patients were diagnosed during 1984-2004 and were followed for death throughout 2008. We used Cox regression models to assess the relationship between serum 25-OHD and risk of death. Results: Three hundred and ninety-nine patients died during follow-up, of whom 343 (86%) died from cancer. Adjusted for sex, age at diagnosis, and season of blood sampling, patients with 25-OHD levels below 46 nmol/L at diagnosis experienced shorter survival. Compared to patients in the lowest quartile of serum 25-OHD, the risk of cancer death among patients in the highest quartile was significantly reduced (HR 0.36 95% CI 0.27, 0.51). The estimated change in risk of cancer death was most pronounced between the first and the second quartile. The associations between 25-OHD levels and survival were observed for all four cancers. Conclusions: Higher circulating serum levels of 25-OHD were positively associated with the survival for cancers of the breast, colon, lung, and lymphoma.

AB - Purpose: We investigated the association between serum levels of 25-hydroxyvitamin D (25-OHD) and risk of death in Norwegian cancer patients. Methods: The study population was 658 patients with cancers of the breast (n = 251), colon (n = 52), lung (n = 210), and lymphoma (n = 145), obtained from JANUS, a population-based serum bank in Norway. Serum samples were collected within 90 days of cancer diagnosis and were analyzed for 25-OHD. Patients were diagnosed during 1984-2004 and were followed for death throughout 2008. We used Cox regression models to assess the relationship between serum 25-OHD and risk of death. Results: Three hundred and ninety-nine patients died during follow-up, of whom 343 (86%) died from cancer. Adjusted for sex, age at diagnosis, and season of blood sampling, patients with 25-OHD levels below 46 nmol/L at diagnosis experienced shorter survival. Compared to patients in the lowest quartile of serum 25-OHD, the risk of cancer death among patients in the highest quartile was significantly reduced (HR 0.36 95% CI 0.27, 0.51). The estimated change in risk of cancer death was most pronounced between the first and the second quartile. The associations between 25-OHD levels and survival were observed for all four cancers. Conclusions: Higher circulating serum levels of 25-OHD were positively associated with the survival for cancers of the breast, colon, lung, and lymphoma.

KW - Cancer patients

KW - Serum

KW - Survival

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=84856759373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856759373&partnerID=8YFLogxK

U2 - 10.1007/s10552-011-9885-6

DO - 10.1007/s10552-011-9885-6

M3 - Article

C2 - 22193397

AN - SCOPUS:84856759373

VL - 23

SP - 363

EP - 370

JO - Cancer Causes and Control

JF - Cancer Causes and Control

SN - 0957-5243

IS - 2

ER -